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Yimplantation (90.0% vs. 89.4%, p¼0.659) were similar between two groups. There was
no difference in MACE rate and occurrence of stent thrombus between the two
groups (p¼NS), however, higher all-cause death rate in the ROTA group at 6 months,
1 and 2 years (p<0.05).
Conclusions: ROTA was used in patients with more lesion complexity. However, the
MACE rate was comparable between ROTA and CA at 6 months, 1 and 2 years.Clinical events
Cutting balloon
(n¼573)
Rotational atherectomy
(n¼413) p value
In-hospital Death/
QWMI/CABG
1.4% 2.0% 0.5166 monthAll-cause death (%) 2.7 7.1 0.007MI (%) 1.8 1.1 0.747TLR (%) 4.0 2.6 0.307Deﬁnite ST (%) 0.5 1.1 0.654Composite MACE 6.5 9.2 0.1841 yearAll-cause death (%) 4.7 10.3 0.007MI (%) 2.6 2.0 0.665TLR (%) 6.3 4.9 0.454Deﬁnite ST (%) 0.6 1.0 0.655Composite MACE (%) 10.6 14.5 0.1452 yearAll-cause death (%) 9.1 15.7 0.025MI (%) 4.5 3.2 0.499TLR (%) 10.3 8.4 0.496Deﬁnite ST (%) 0.7 1.4 0.655Composite MACE (%) 18.2 22.8 0.205MI: Myocardial infarction; QWMI: Q-wave myocardial infarction; CABG: Coronary artery bypass
grafting; TLR: Target lesion revascularization; ST: Stent thrombus; MACE: Major adverse cardiac
events.
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Background: Newer generation stents by means of more biocompatible components
limiting inﬂammatory response have led to signiﬁcant improvement in the cardio-
vascular outcomes.
Objective: The purpose of the present study is to evaluate the long term outcomes of
diabetic patients undergoing multivessel PCI with the use of everolimus-eluting stent
(EES).
Methods: 350 consecutive diabetic patients that underwent multivessel PCI deﬁned
as 2 vessel with EES during the same index procedure were analyzed. Patients were
further stratiﬁed by the need for insulin (n¼55) or oral medications only (n¼82) for
control of blood glucose in comparison once that were non-diabetic (n¼214). Primary
end point (MACE) was the combined incidence of death, and non-fatal Q-wave
myocardial and target vessel revascularization (TVR) at one year.
Results:Diabetic group had more African-Americans, and higher hypertension, renal
failure and higher body mass index compared to non-diabetics. At 1 year there was no
difference in rates of MACE, between the non-diabetics and oral diabetics (7% vs.
12%, p¼0.15) but the MACE rates were higher in insulin treated diabetics compared
to non-diabetics (24% vs. 7%, p<0.001). Similar trends were noted with TVR, with
no difference between non-diabetics and oral diabetics (4.3% vs. 10%, p¼0.09) but
signiﬁcantly higher TVR rate in the insulin group compared to non-diabetics (20% vs.4.3%, p<0.001). There were no differences in the over-all mortality and no cases of
deﬁnitive stent thrombosis were noted in the entire cohort at 1 year.
Conclusions: Despite the higher risk nature of multivessel intervention in diabetic
patients, with the use of newer generation EES stents, the event rates at one year in
oral-diabetics were similar to the non-diabetic population. But patients with insulin
treated diabetes continue to be a challenging population.Coronary
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Background: There are clinic and genetic polymorphism differences in coronary ar-
tery disease (CHD). Percutaneous coronary intervention (PCI), clinic, angiographic,
procedure technique may inﬂuence the evolution, major events (death, AMI, revas-
cularization) and clinical restenosis. This study aims to evaluate if there are genetic
polymorphism differences between patients with and without CHD and if it would
inﬂuence in long-term follow-up after PCI.
Method and Results: It was studied two groups: the coronary disease group (CDG)
with 182 patients of a closed health system with CHD that were submitted to PCI
from 2001 and 2007 and to genetic follow-up evaluation until 12/31/2008; the control
group (CG) with 36 patients, were angiographically normal and were also submitted to
genetic evaluation. The polymorphisms evaluated were the ACE I/D and A166C
(AT1R). In this period 221 procedures were performed in 182 patients of CDG. Qui
square, Fisher exact and Student t test were used. Cox multivariate regression analysis
were not performed because only three clinical characteristics and A166C had p<0.10
in univariable analysis.
The CG and CDG patients were: female 20 (55.6%) and 49 (26.9%), (P¼0.0007);
age 55.911.1 and 60.810.5 (P¼0.0100); tobacco smokers 5 (13.9%) and 67
(36.8%), (P¼0.0132); diabetes 4 (11.1%) and 48 (26.4%), (P¼0.0802); hypertension
29 (80.6%) and 146 (80.2%), (P¼0.9631); dyslipidemia 14 (38.9%) and 112 (61.5%),
(P¼0.0119); family history 12 (33.3%) and 60 (33.0%), (P¼0.9659); obesity 9 (25.0%)
and 60 (33.0%), (P¼0.3476); ACE polymorphism DD 16 (44.5%), DI 17 (47.2%), II
3 (8.3%) and DD 81 (44.5%), DI 70 (38.5%), II 31 (17.0%), (P¼0.3612); A166C
